During the last session, Third Harmonic Bio Inc (NASDAQ:THRD)’s traded shares were 0.42 million, with the beta value of the company hitting 2.86. At the end of the trading day, the stock’s price was $15.06, reflecting an intraday gain of 2.24% or $0.33. The 52-week high for the THRD share is $16.94, that puts it down -12.48 from that peak though still a striking 61.75% gain since the share price plummeted to a 52-week low of $5.76. The company’s market capitalization is $618.97M, and the average intraday trading volume over the past 10 days was 0.49 million shares, and the average trade volume was 146.40K shares over the past three months.
Third Harmonic Bio Inc (THRD) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. THRD has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.3.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Third Harmonic Bio Inc (NASDAQ:THRD) trade information
Third Harmonic Bio Inc (THRD) registered a 2.24% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.24% in intraday trading to $15.06, hitting a weekly high. The stock’s 5-day price performance is 10.98%, and it has moved by 25.60% in 30 days. Based on these gigs, the overall price performance for the year is 146.89%. The short interest in Third Harmonic Bio Inc (NASDAQ:THRD) is 1.86 million shares and it means that shorts have 27.54 day(s) to cover.
The consensus price target of analysts on Wall Street is $19, which implies an increase of 20.74% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.6 and $23 respectively. As a result, THRD is trading at a discount of -52.72% off the target high and 76.1% off the low.
Third Harmonic Bio Inc (THRD) estimates and forecasts
Statistics show that Third Harmonic Bio Inc has underperformed its competitors in share price, compared to the industry in which it operates. Third Harmonic Bio Inc (THRD) shares have gone up 61.41% during the last six months, with a year-to-date growth rate less than the industry average at -34.62% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -57.90% this quarter and then drop -88.20% in the quarter after that.
While earnings are projected to return -42.02% in 2024.
THRD Dividends
Third Harmonic Bio Inc is due to release its next quarterly earnings on 2024-Aug-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Third Harmonic Bio Inc (NASDAQ:THRD)’s Major holders
Third Harmonic Bio Inc insiders own 9.92% of total outstanding shares while institutional holders control 98.12%, with the float percentage being 108.93%. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the largest shareholder of the company, while 110.0 institutions own stock in it. As of 2024-06-30, the company held over 10.91 million shares (or 26.8961% of all shares), a total value of $141.8 million in shares.
The next largest institutional holding, with 5.78 million shares, is of ORBIMED ADVISORS LLC’s that is approximately 14.2498% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $75.13 million.
